Peers EXCEL for Type 2 Diabetes Mellitus

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
University of Wisconsin, Madison, WI
Type 2 Diabetes Mellitus
Peers LEAD - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of the study is to gather input about the value of adding a newly developed diabetes self-management program to an existing diabetes self-management program. Participants will self-identify as African-American/Black with type 2 diabetes, and prescribed a diabetes medication. Participants can expect to be in the study for 6 months.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Baseline, 2 months, 6 months

Month 6
Acceptability of intervention
Change in blood glucose (hemoglobin A1C)
Feasibility of intervention
Medication adherence

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Healthy Living with Diabetes (HLWD)
1 of 2
Peers EXCEL
1 of 2
Active Control
Experimental Treatment

24 Total Participants · 2 Treatment Groups

Primary Treatment: Peers EXCEL · No Placebo Group · N/A

Peers EXCELExperimental Group · 2 Interventions: Peers LEAD, HLWD · Intervention Types: Behavioral, Behavioral
Healthy Living with Diabetes (HLWD)
Behavioral
ActiveComparator Group · 1 Intervention: HLWD · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, 2 months, 6 months
Closest Location: University of Wisconsin · Madison, WI
Photo of wi university of wisconsin  1Photo of madison  2Photo of madison  3
2003First Recorded Clinical Trial
1 TrialsResearching Type 2 Diabetes Mellitus
380 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 9 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have been diagnosed with diabetes for at least 1 year.
You have type 2 diabetes.
You have a primary care provider who prescribes one diabetes medication.
Self-reported nonadherence on the DOSE-nonadherence survey.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.